e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Cell signalling and inflammation: what's new in 2013?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model
M. Leduc, B. Grouix, L. Gervais, F. Sarra-Bournet, M. Tremblay, P. Laurin, L. Gagnon (Laval, Canada)
Source:
Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Session:
Cell signalling and inflammation: what's new in 2013?
Session type:
Poster Discussion
Number:
4746
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Leduc, B. Grouix, L. Gervais, F. Sarra-Bournet, M. Tremblay, P. Laurin, L. Gagnon (Laval, Canada). PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model. Eur Respir J 2013; 42: Suppl. 57, 4746
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The cryoTBB role in the diagnostic work-up of IPF: an European perspective; emergent standardization guidelines
Pathology of ILDs
Pathology of pulmonary hypertension
Related content which might interest you:
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Targetingpyruvate kinase M2 isoform inhibits proliferation of human lung fibroblasts
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Bromodomain inhibitor JQ1 attenuates TGF-beta-suppressed
SOD2
expression and reduces proliferation in human primary pulmonary fibroblasts
Source: Annual Congress 2013 –The multiple faces of stress in lung injury
Year: 2013
BIBF1120 inhibits fibroblasts proliferation and production of the extracellular matrix protein fibulin-1
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
A role of Foxc2 gene in mice with bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Simultaneous inhibition of CTGF and Autotaxin reduces lung fibrosis and improves lung function in mice
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Year: 2021
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
The enhancement of Stanniocalcin-1 (STC1) secretion increases the ability of mesenchymal stem cells (MSCs) to reduce bleomycin-induced lung fibrosis in a mouse model through inhibition of endoplasmic reticulum stress (ER-stress)/TGFbeta1 pathway
Source: International Congress 2014 – ILDs 1
Year: 2014
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
ATF3 regulates PINK1 transcription in lung epithelial cells of the aging lung
Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung
Year: 2016
17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Source: Eur Respir J 2010; 35: 496-504
Year: 2010
Inhibition of the Arp2/3 complex inhibits lung myofibroblast differentiation in vitro and attenuates bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Year: 2019
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Reactivation of developmental pathways in idiopathic pulmonary fibrosis: FGF9 and FGF18 modulate the phenotype of control and fibrotic human lung fibroblasts in vitro
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Reduction of lung injury and fibrosis by human embrionic stem cells in a mouse model of silica-induced lung fibrosis
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011
The effects of tobramycin on pulmonary fibroblast function
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept